Print

European Experience and Evidence of Physician-led Switching of Biological Medicines Give Hope to Patients around the World

March 14, 2017 - On 9th March, IFPMA launched jointly with EFPIA and EBE a position paper entitled Considerations for physicians on switching decisions regarding biosimilars. Physician-led switching of biological medicines is a well-known medical practice. Although data on the frequency of switching in clinical practice is scarce, no evidence from clinical trials or post marketing surveillance data has found that switching to or from different biotherapeutics leads to safety concerns.

Print

IGBA Statement on the Final Report of the United Nations Secretary General’s High Level Panel on Access to Medicines

November 15, 2016 – Geneva, Switzerland – The International Generic and Biosimilar Medicines Association (IGBA) believes that generic and biosimilar medicines can play a fundamental role in improving access to high quality medicines for patients worldwide.

Print

IGBA Joins ICH and Welcomes the Positive Vote of the General Assembly

Geneva, Switzerland (June 15, 2016) The International Generic and Biosimilar Medicines Association (IGBA) very much welcomes today’s decision of the ICH General Assembly to accept the IGBA as an Assembly Member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).

Contact Info

IGBA | INTERNATIONAL GENERIC AND BIOSIMILAR MEDICINES ASSOCIATION

Rue d'Arlon, 50
B-1000 Brussels, Belgium

Telephone: +32 (0)2 736 84 11
Fax: +32 (0)2 736 74 38
E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.